Mortensen S, Agertoft L, Husby S, Pedersen S
Kolding Sygehus, paediatrisk afdeling.
Ugeskr Laeger. 1994 Nov 7;156(45):6661-3.
The aim of this prospective, randomised, double blind study was to evaluate whether inhaled nebulized corticosteroid is effective in the treatment of croup. Thirty-seven children (aged 0.4-4.9 years) admitted to hospital with moderate to severe croup were allocated to treatment with either 2 mg nebulized budesonide (20) or saline (17). Disease severity was assessed by a clinical croup score based on stridor, cough, retractions, dyspnoea and cyanosis, and the overall clinical assessment was scored on a visual log scale (0-100). Two hours after treatment there was a significant improvement in croup score in the group treated with budesonide (8 to 4.5), but not in the group treated with saline (8 to 8). Furthermore, the overall clinical assessment score decreased significantly (50 to 25) in the group treated with budesonide, whereas it remained constant in the placebo group (60 to 62). The results indicate that nebulised budesonide can be used as a safe and effective alternative treatment in children with moderate to severe croup.
这项前瞻性、随机、双盲研究的目的是评估雾化吸入皮质类固醇激素治疗喉炎是否有效。37名因中度至重度喉炎入院的儿童（年龄0.4 - 4.9岁）被随机分为两组，分别接受2毫克布地奈德雾化治疗（20例）或生理盐水雾化治疗（17例）。根据喘鸣、咳嗽、吸气凹陷、呼吸困难和发绀情况，通过临床喉炎评分评估疾病严重程度，并采用视觉对数量表（0 - 100）对整体临床评估进行评分。治疗两小时后，布地奈德治疗组的喉炎评分有显著改善（从8分降至4.5分），而生理盐水治疗组则无改善（仍为8分）。此外，布地奈德治疗组的整体临床评估评分显著降低（从50分降至25分），而安慰剂组则保持不变（从60分降至62分）。结果表明，雾化布地奈德可作为中度至重度喉炎患儿安全有效的替代治疗方法。
